However, apparently benign breast disease seen on benign biopsies is a limiting factor for diagnosis and a risk factor of breast cancer especially in the high-risk category patients. Hypothesizing that molecular changes often occur before morphological variations, the levels of the LncRNA H19 were...
Unfortunately, to date, markers with such characteristics have not made it to the clinic for breast cancer. Past years, many studies indicated that the non-coding part of our genome (the so called 'junk' DNA), may be an ideal source for these biomarkers. In this chapter, the potential ...
MALAT1 has previously been described as a metastasis-promoting long noncoding RNA (lncRNA). We show here, however, that targeted inactivation of the Malat1 gene in a transgenic mouse model of breast cancer, without altering the expression of its adjacent
proliferation, and apoptosis is critical for the normal development and homeostasis of breast cells. The premalignant stages change this balance and the regulatory biomarkers of the
It has been suggested that melatonin may be a therapeutic strategy for MYB-miRNA-induced glioma [110]. A negative correlation between MYB and miR-143-3p expression was found in breast cancer tissues and cells. More importantly, MYB is involved in regulating the proliferation and apoptosis of ...
The modulation of lncRNA expression through RNA interference (RNAi) techniques, such as the use of small interfering RNA (siRNA) or short hairpin RNA (shRNA), offers a targeted approach to silence oncogenic lncRNAs in vivo. For instance, targeting HOTAIR in breast cancer and MALAT1 across var...
MYC regulated long non-coding RNAs could have roles in development of breast cancerLentiviral vectors are powerful tools for gene expression studies. Here we report the construction of pTIJ, a vector for inducible gene expression. pTIJ was generated from pTRIPZ backbone, which is designed for the...
For example, the CCVs within the same signal that lie outside of mencRNA exons could potentially effect mencRNA expression through alteredcis-regulatory elements (e.g., mencRNA promoters or enhancers). Consistent with this, for 4/7 mencRNA eQTLs that overlap breast cancer risk signals, the e...
Thus, new biomarkers are urgently needed to enhance the diagnosis of breast cancer. The lncRNAs discussed above are closely related to the clinical outcomes of breast cancer patients, and may function as potential diagnostic biomarkers for breast cancer treatment in the future. 3. LncRNAs Regulate ...
As of yet, no non-coding RNAs (ncRNAs) are used in commercial diagnostic tests; however, there is great interest in identifying circulating microRNAs (miRNAs) [14–16] and long non-coding RNAs (lncRNAs) [17–19] in breast cancer diagnosis and for monitoring therapeutic response. Over the ...